Perhaps even worse than like-for-like competitors for Novo Nordisk, some of these experimental drugs could gain market access as products for long-term weight maintenance, rather than rapid weight loss
[14] TALENEZHAD, N
Imagine the impact such weight loss could have on your health and quality of life
To properly manage opportunities and challenges surrounding these drugs, payers should take some key actions related to the coverage of GLP-1 prescriptions for weight loss
To complement the Jadad score, the Cochrane Risk of Bias Tool (RoB 2) (Sterne et al., 2019) was also used for RCTs to provide a domain-based qualitative evaluation, assessing risks related to selection, performance, detection, attrition, and reporting
aureus strains (Extended Data Fig